Kyntra Bio (KYNB) Accumulated Depreciation (2014 - 2023)

Kyntra Bio has disclosed Accumulated Depreciation across 10 years of filings, most recently posting $113.0 million for Q4 2023.

• In Q4 2023, Accumulated Depreciation fell 12.22% year-over-year to $113.0 million; the TTM figure through Dec 2023 stood at $113.0 million (down 12.22% YoY), while the FY2023 annual figure was $113.0 million, down 12.22% from the prior year.
• Accumulated Depreciation came in at $113.0 million for Q4 2023 at Kyntra Bio, down from $128.7 million in the prior quarter.
• In the past five years, Accumulated Depreciation ranged from a high of $128.7 million in Q4 2022 to a low of $93.2 million in Q1 2019.
• Average Accumulated Depreciation over 5 years is $109.0 million, with a median of $109.4 million recorded in 2020.
• Year-over-year, Accumulated Depreciation surged 53.93% in 2019 and slipped 12.22% in 2023.
• Over 5 years, Accumulated Depreciation stood at $100.4 million in 2019, then advanced by 10.84% to $111.2 million in 2020, then increased by 8.77% to $121.0 million in 2021, then grew by 6.34% to $128.7 million in 2022, then fell by 12.22% to $113.0 million in 2023.
• Per Business Quant data, the three most recent Accumulated Depreciation figures were $113.0 million in Q4 2023, $128.7 million in Q4 2022, and $121.0 million in Q4 2021.